We also examined the effects of the P-gp/BCRP inhibitor elacridar on response to ABT-751 in a P-gp over-expressing cell line model, DLKP-A, as well as melanoma models of varying drug efflux transporter expression. This evidence concerns the gene PGP and melanoma.